Livforsakringsbolaget Skandia, Omsesidigt Halozyme Therapeutics, Inc. Transaction History
Livforsakringsbolaget Skandia, Omsesidigt
- $2.1 Billion
- Q2 2025
A detailed history of Livforsakringsbolaget Skandia, Omsesidigt transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Livforsakringsbolaget Skandia, Omsesidigt holds 102,000 shares of HALO stock, worth $5.77 Million. This represents 0.25% of its overall portfolio holdings.
Number of Shares
102,000
Previous 19,090
434.31%
Holding current value
$5.77 Million
Previous $993,000
434.34%
% of portfolio
0.25%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding HALO
# of Institutions
594Shares Held
124MCall Options Held
320KPut Options Held
113K-
Black Rock Inc. New York, NY17.6MShares$997 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$726 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$342 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$220 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$208 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.88B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...